HAE Market Developments During Q3 2025 in Product Approvals and Patient Engagement

During Q3 2025, the hereditary angioedema market was marked by significant developments in research, awareness, and patient support.

BioCryst and Orladeyo maintained community engagement via the “This AND” campaign, summit participation, and educational efforts.

CSL promoted Andembry’s approval for HAE prevention with messaging that included patient testimonials and treatment support resources.

Ionis announced Phase 3 results and introduced Dawnzera, the first RNA-targeted therapy for HAE.

KalVista received FDA approval for Ekterly, the first oral on-demand HAE treatment, while continuing to support patients through the KalVista Cares program and the Mind the HAE Attack campaign.